{"groups":[{"description":"Fludarabine 30 mg/m\\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).\n\nMelphalan 140 mg/m\\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\\^2 IV infused starting on day -5.","id":"FG000","title":"Fludarabine + Melphalan + Stem Cell Infusion"},{"description":"Fludarabine 30 mg/m\\^2 IV daily over 30 minutes for 4 Days (Beginning Day -4).\n\nLower-Dose Melphalan 100 mg/m\\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\\^2 IV infused starting on day -5.","id":"FG001","title":"Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the 52 participants enrolled, two were not included due to one patient experiencing pulmonary complication and another not completing the study follow up requirement.","recruitmentDetails":"Recruitment Period: January 18, 2002 to July 27, 2011. All recruitment done in a medical clinical setting."}